Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics reported late-stage data for aficamten in a genetic heart condition, showing significant improvement in patients’ symptoms and exercise capacity, in a setting with no approved treatments. The results are a meaningful clinical milestone that could strengthen the drug’s regulatory prospects and investor outlook.